KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-cash Items (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Non-cash Items for 8 consecutive years, with $56982.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 97.36% to $56982.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56982.0 through Dec 2025, down 97.36% year-over-year, with the annual reading at $56982.0 for FY2025, 97.36% down from the prior year.
  • Non-cash Items hit $56982.0 in Q4 2025 for Adaptive Biotechnologies, down from $15.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $300.8 million in Q2 2021 to a low of $56982.0 in Q4 2025.
  • Historically, Non-cash Items has averaged $46.4 million across 5 years, with a median of $6.0 million in 2022.
  • Biggest five-year swings in Non-cash Items: crashed 99.21% in 2024 and later surged 24370.0% in 2025.
  • Year by year, Non-cash Items stood at $156.1 million in 2021, then tumbled by 95.74% to $6.7 million in 2022, then plummeted by 92.39% to $506000.0 in 2023, then soared by 326.28% to $2.2 million in 2024, then crashed by 97.36% to $56982.0 in 2025.
  • Business Quant data shows Non-cash Items for ADPT at $56982.0 in Q4 2025, $15.4 million in Q3 2025, and $29.4 million in Q2 2025.